Navigation Links
It's a knock out: eIF4E-specific anti-sense oligonucleotides knock down cancer
Date:9/4/2007

A new study by Jeremy Graff and colleagues from Eli Lilly and Company has demonstrated the anti-cancer effect of a new therapeutic in a mouse model of human tumors and has spawned clinical trials to test the ability of this therapeutic to treat human cancers. As highlighted in the accompanying commentary by Celeste Simon and colleagues from the University of Pennsylvania, Philadelphia, if the therapeutic is as effective in clinical trials as it was in mice it will be useful for the treatment of a broad range of cancers.

The growth of many tumors is promoted by increased expression of the protein eIF4E, but no eIF4E-specific therapy has yet been developed. In this study, the intravenous administration of eIF4E-specific antisense oligonucleotides (ASOs) to mice bearing human tumors substantially inhibited tumor growth. Importantly, although these ASOs also decreased eIF4E expression in normal tissues, the function of the normal tissues analyzed was not compromised. The authors therefore suggest that tumor cells are more susceptible to decreased expression of eIF4E than normal cells, meaning that eIF4E-specific ASOs should not cause damage to normal tissues.

TITLE: Therapeutic suppression of translation initiation factor eIF4E expression reduces tumor growth without toxicity

AUTHOR CONTACT:

Jeremy R. Graff
Eli Lilly and Company, Indianapolis, Indiana, USA.
Phone: (317) 277-0220; Fax: (317) 277-3652; E-mail: graff_jeremy@lilly.com.

View the PDF of this article at: https://www.the-jci.org/article.php?id=32044

ACCOMPANYING COMMENTARY:

TITLE: Taking aim at translation for tumor therapy

AUTHOR CONTACT:

M. Celeste Simon
Abramson Family Cancer Institute, University of Pennsylvania School of Medicine, Philadelphia, Pennsylvania, USA.
Phone: (215) 746-5532; Fax: (215) 746-5511; E-mail: celeste2@mail.med.upenn.edu.

View the PDF of this article at: https://www.the-jci.org/article.php?id=33107


'/>"/>
Contact: Karen Honey
press_releases@the-jci.org
215-573-1850
Journal of Clinical Investigation
Source:Eurekalert

Related medicine news :

1. Alcohol a potential carcinogen: knocking on the door: pay heed!
2. Knock on the Head – No Small Thing After Al
3. Lethal Hospital Bug Tough to Knock Down, Statistics Reveal
4. The Tech Savvy Patient Knocks on the Doors of Telemedicine and Virtual Clinics
5. Knocking Out Survival Protein Could Aid Leukemia Treatment
6. Knocking Out Survival Protein Could Fight Leukemia
7. Chilean Presidents Cousin Successfully Tests Allergy Knockout Technique on Mice
8. Anti-Sense Drugs and Nanotechnology Offer New Hope In Cancer Fight
9. Fibroids unlikely to Turn Cancerous
10. Virus Level could Predict Cervical Cancer Risk
11. Cancer Doctors Okays Controversial Prostate Therapy
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/26/2016)... ... ... Brent Kasmer, a legally blind and certified personal trainer is helping to develop a weight ... app plans to fix the two major problems leading the fitness industry today:, ... program , They don’t eliminate all the reasons people quit their exercise program ...
(Date:6/25/2016)... Washington, D.C. (PRWEB) , ... June 25, 2016 ... ... will discuss health policy issues and applications at AcademyHealth’s Annual Research Meeting June ... share their work on several important health care topics including advance care planning, ...
(Date:6/25/2016)... ... June 25, 2016 , ... The temporary closing of Bruton Memorial Library on June 21 due ... up a new, often overlooked aspect of head lice: the parasite’s ability to live away ... a common occurrence, but a necessary one in the event that lice have simply gotten ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... Oklahoma City, Oklahoma (PRWEB) , ... June 25, ... ... to helping both athletes and non-athletes recover from injury. Recently, he has implemented ... for the Oklahoma City area —Johnson is one of the first doctors to ...
Breaking Medicine News(10 mins):
(Date:6/23/2016)... , June 23, 2016 ... CAPR ), a biotechnology company focused on ... today announced that patient enrollment in its ongoing ... Duchenne) has exceeded 50% of its 24-patient target. ... in the third quarter of 2016, and to ...
(Date:6/23/2016)... BOGOTA, Colombia , June 23, 2016  Astellas today announced the establishment of Astellas Farma Colombia (AFC), ... company,s second affiliate in Latin America . ... ... Colombia ... ...
(Date:6/23/2016)... 23, 2016  Experian Health, the healthcare ... the patient payment and care experience, today ... products and services that will enhance the ... offerings. These award-winning solutions will enable healthcare ... compliant in an ever-changing environment and redefine ...
Breaking Medicine Technology: